Santos da Silva Jorge's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Feb 20, 2024
- Accession no.
- 0001213900-24-015446
- Filed
- Feb 20, 2024
- Trade date
- Feb 15-20, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.56M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Santos da Silva JorgeCIK 0001920509 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −20,000 | $60.18 | −$1,203,600 | 3,147,554 | Direct | |
| Feb 16, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −20,000 | $60.15 | −$1,203,000 | 3,127,554 | Direct | |
| Feb 20, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −20,000 | $57.44 | −$1,148,800 | 3,107,554 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.